Business Context and Reporting Period
This Form 8-K Current Report was filed by Cyclacel Pharmaceuticals, Inc. on January 13, 2010. The filing discloses the completion of a "registered direct" equity offering to institutional investors. Note: The request metadata references "Bio Green Med Solution, Inc.," but the filing text explicitly identifies the registrant as Cyclacel Pharmaceuticals, Inc.
Key Financial Metrics
- Offering Size: 2,850,000 units sold.
- Price per Unit: $2.51.
- Unit Composition: One share of Common Stock plus one warrant to purchase 0.25 of a share.
- Net Proceeds: Approximately $6.6 million (after deducting placement agent fees and offering expenses).
- Warrant Terms: Five-year term; exercisable beginning six months after issuance at an exercise price of $3.26 per share.
- Post-Offering Share Count: 28,964,653 shares of Common Stock issued and outstanding.
Material Changes
The primary material change is the increase in outstanding common stock and the infusion of capital resulting from the closing of the registered direct offering. The filing does not provide comparative financial data (revenue, profit, or cash flow) for prior periods as this is a current event report rather than a periodic financial statement.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that internet address information is not incorporated into the report. The transaction was facilitated by ROTH Capital Partners, LLC (Placement Agent) and Merriman Curhan Ford (Financial Advisor).
Investor Verification Checklist
- Verify the exact net proceeds of $6.6 million against the gross proceeds (2,850,000 units x $2.51) to confirm the total amount of fees and expenses deducted.
- Confirm the dilution impact of the 2,850,000 new shares on existing shareholders.
- Review the attached press release (Exhibit 99.1) for details on the intended use of the raised capital.
- Monitor the warrant exercise price of $3.26 relative to the current market price to assess potential future dilution.